Cargando…

Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia

Neonatal platelets are hypo-reactive to the tyrosine kinase-linked receptor agonist collagen. Here, we have investigated whether the hypo-responsiveness is related to altered levels of glycoprotein VI (GPVI) and integrin α2β1, or to defects in downstream signalling events by comparison to platelet a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy, Alexander T., Palma-Barqueros, Verónica, Watson, Stephanie K., Malcor, Jean-Daniel, Eble, Johannes A., Gardiner, Elizabeth E., Blanco, José E., Guijarro-Campillo, Rafael, Delgado, Juan L., Lozano, María L., Teruel-Montoya, Raúl, Vicente, Vicente, Watson, Steve P., Rivera, José, Ferrer-Marín, Francisca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Schattauer GmbH 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202930/
https://www.ncbi.nlm.nih.gov/pubmed/29695020
http://dx.doi.org/10.1055/s-0038-1646924
_version_ 1783365783910350848
author Hardy, Alexander T.
Palma-Barqueros, Verónica
Watson, Stephanie K.
Malcor, Jean-Daniel
Eble, Johannes A.
Gardiner, Elizabeth E.
Blanco, José E.
Guijarro-Campillo, Rafael
Delgado, Juan L.
Lozano, María L.
Teruel-Montoya, Raúl
Vicente, Vicente
Watson, Steve P.
Rivera, José
Ferrer-Marín, Francisca
author_facet Hardy, Alexander T.
Palma-Barqueros, Verónica
Watson, Stephanie K.
Malcor, Jean-Daniel
Eble, Johannes A.
Gardiner, Elizabeth E.
Blanco, José E.
Guijarro-Campillo, Rafael
Delgado, Juan L.
Lozano, María L.
Teruel-Montoya, Raúl
Vicente, Vicente
Watson, Steve P.
Rivera, José
Ferrer-Marín, Francisca
author_sort Hardy, Alexander T.
collection PubMed
description Neonatal platelets are hypo-reactive to the tyrosine kinase-linked receptor agonist collagen. Here, we have investigated whether the hypo-responsiveness is related to altered levels of glycoprotein VI (GPVI) and integrin α2β1, or to defects in downstream signalling events by comparison to platelet activation by C-type lectin-like receptor 2 (CLEC-2). GPVI and CLEC-2 activate a Src- and Syk-dependent signalling pathway upstream of phospholipase C (PLC) γ2. Phosphorylation of a conserved YxxL sequence known as a (hemi) immunotyrosine-based-activation-motif (ITAM) in both receptors is critical for Syk activation. Platelets from human pre-term and full-term neonates display mildly reduced expression of GPVI and CLEC-2, as well as integrin αIIbβ3, accounted for at the transcriptional level. They are also hypo-responsive to the two ITAM receptors, as shown by measurement of integrin αIIbβ3 activation, P-selectin expression and Syk and PLCγ2 phosphorylation. Mouse platelets are also hypo-responsive to GPVI and CLEC-2 from late gestation to 2 weeks of age, as determined by measurement of integrin αIIbβ3 activation. In contrast, the response to G protein-coupled receptor agonists was only mildly reduced and in some cases not altered in neonatal platelets of both species. A reduction in response to GPVI and CLEC-2, but not protease-activated receptor 4 (PAR-4) peptide, was also observed in adult mouse platelets following immune thrombocytopenia, whereas receptor expression was not impaired. Our results demonstrate developmental differences in platelet responsiveness to GPVI and CLEC-2, and also following immune platelet depletion leading to reduced Syk activation. The rapid generation of platelets during development or following platelet depletion is achieved at the expense of signalling by ITAM-coupled receptors.
format Online
Article
Text
id pubmed-6202930
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Schattauer GmbH
record_format MEDLINE/PubMed
spelling pubmed-62029302018-10-30 Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia Hardy, Alexander T. Palma-Barqueros, Verónica Watson, Stephanie K. Malcor, Jean-Daniel Eble, Johannes A. Gardiner, Elizabeth E. Blanco, José E. Guijarro-Campillo, Rafael Delgado, Juan L. Lozano, María L. Teruel-Montoya, Raúl Vicente, Vicente Watson, Steve P. Rivera, José Ferrer-Marín, Francisca Thromb Haemost Neonatal platelets are hypo-reactive to the tyrosine kinase-linked receptor agonist collagen. Here, we have investigated whether the hypo-responsiveness is related to altered levels of glycoprotein VI (GPVI) and integrin α2β1, or to defects in downstream signalling events by comparison to platelet activation by C-type lectin-like receptor 2 (CLEC-2). GPVI and CLEC-2 activate a Src- and Syk-dependent signalling pathway upstream of phospholipase C (PLC) γ2. Phosphorylation of a conserved YxxL sequence known as a (hemi) immunotyrosine-based-activation-motif (ITAM) in both receptors is critical for Syk activation. Platelets from human pre-term and full-term neonates display mildly reduced expression of GPVI and CLEC-2, as well as integrin αIIbβ3, accounted for at the transcriptional level. They are also hypo-responsive to the two ITAM receptors, as shown by measurement of integrin αIIbβ3 activation, P-selectin expression and Syk and PLCγ2 phosphorylation. Mouse platelets are also hypo-responsive to GPVI and CLEC-2 from late gestation to 2 weeks of age, as determined by measurement of integrin αIIbβ3 activation. In contrast, the response to G protein-coupled receptor agonists was only mildly reduced and in some cases not altered in neonatal platelets of both species. A reduction in response to GPVI and CLEC-2, but not protease-activated receptor 4 (PAR-4) peptide, was also observed in adult mouse platelets following immune thrombocytopenia, whereas receptor expression was not impaired. Our results demonstrate developmental differences in platelet responsiveness to GPVI and CLEC-2, and also following immune platelet depletion leading to reduced Syk activation. The rapid generation of platelets during development or following platelet depletion is achieved at the expense of signalling by ITAM-coupled receptors. Schattauer GmbH 2018-06 2018-04-25 /pmc/articles/PMC6202930/ /pubmed/29695020 http://dx.doi.org/10.1055/s-0038-1646924 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hardy, Alexander T.
Palma-Barqueros, Verónica
Watson, Stephanie K.
Malcor, Jean-Daniel
Eble, Johannes A.
Gardiner, Elizabeth E.
Blanco, José E.
Guijarro-Campillo, Rafael
Delgado, Juan L.
Lozano, María L.
Teruel-Montoya, Raúl
Vicente, Vicente
Watson, Steve P.
Rivera, José
Ferrer-Marín, Francisca
Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia
title Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia
title_full Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia
title_fullStr Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia
title_full_unstemmed Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia
title_short Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia
title_sort significant hypo-responsiveness to gpvi and clec-2 agonists in pre-term and full-term neonatal platelets and following immune thrombocytopenia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202930/
https://www.ncbi.nlm.nih.gov/pubmed/29695020
http://dx.doi.org/10.1055/s-0038-1646924
work_keys_str_mv AT hardyalexandert significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT palmabarquerosveronica significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT watsonstephaniek significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT malcorjeandaniel significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT eblejohannesa significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT gardinerelizabethe significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT blancojosee significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT guijarrocampillorafael significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT delgadojuanl significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT lozanomarial significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT teruelmontoyaraul significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT vicentevicente significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT watsonstevep significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT riverajose significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia
AT ferrermarinfrancisca significanthyporesponsivenesstogpviandclec2agonistsinpretermandfulltermneonatalplateletsandfollowingimmunethrombocytopenia